George Clinical welcomes the recent announcement by our partner organization, West Cancer Center of their intention to join OneOncology in January 2019. The announcement sees a departure from their existing relationship with Methodist Le Bonheur Healthcare, an affiliation they have held since 2011. The affiliation with OneOncology will place West Cancer Center as a nationally […]
Read MoreSYDNEY, January 22, 2019 – George Clinical, headquartered in Sydney, Australia, a global scientifically backed CRO, today announced the appointment of James Cheong to the role of Chief Operating Officer. With extensive management experience spanning over two decades, Cheong brings valuable leadership to George Clinical’s executive team during a period of strong expansion and growth. […]
Read MoreGeorge Clinical welcomes The Taiwan Food and Drug Administration’s (TFDA) recent clarified timelines for approval of a general Clinical Trial Authority (CTA) at 45 calendar days. The announcement, released by the TFDA in October, adds to the suite of attractive options to expedite clinical trial regulatory approval timelines in Taiwan. This includes the existing 15 […]
Read MoreThe importance of securing strong, long-standing investigator networks with leading research hospitals and clinics is critical to the continued growth of the clinical trial environment in countries such as Taiwan, says Evon Hui, Head of Business Operations, East Asia. Over the past 15 years, George Clinical has cultivated an enviable network of MOUs that have […]
Read MoreGeorge Clinical, a leading clinical research organization (CRO) in the Asia-Pacific region, has gained recognition of the organization’s strong support of the Mandatory Provident Fund (MPF) legislation, and their provision of good MPF benefits. The Mandatory Provident Fund Schemes Authority (MPFA) awarded George Clinical their Good MPF Employer Award at a ceremony in Hong Kong […]
Read MoreGeorge Clinical welcomes the decision by the FDA to approve the delivery of CAR-T therapy in a partnership between Methodist Healthcare, and George Clinical Scientific Leader, Dr. Jason Chandler of West Cancer Center. Car-T therapies are at the cutting edge of treatment for a range of cancers. The recent announcement by the FDA, West Cancer […]
Read MoreBeijing, November 13, 2018 – George Clinical, a leading clinical research organization (CRO) in the Asia-Pacific region, has continued its involvement and collaboration with the Heart Health Research Center (HHRC), further developing the depth and quality of investigator networks. The HHRC, a collaborative initiative developed by Cardio Union, an emerging multi-disciplinary healthcare organization and the […]
Read More9 AUGUST, 2018 – (BEIJING) In another positive development in China’s rapidly evolving regulatory environment The China National Drug Administration (CNDA) has introduced a 60-day window for clinical trial approvals, mirroring US FDA protocols. The rules have taken immediate effect. “This new ruling has major implications for sponsors wishing to conduct China-only or multi-centre studies […]
Read More
In another encouraging step towards making China a leading destination for clinical drug trials, some critical developments were announced at The Executive Meeting of the State Council on the 12th April 2018. From 1 May 2018, the import tariff of all common drugs including anticancer drugs, alkaloids with anticancer effects and the imported Chinese patent […]
Read More
George Clinical, a leading full-service CRO in the US and Asia-Pacific region, is pleased to announce that Matthew Reabold, Sr. has been promoted to the Head of Business Development, USA. George Clinical, headquartered in Sydney, Australia, operates in fifteen countries around the world and has major operational hubs in the USA, East Asia, China, and India. Matthew, who is USA based, will […]
Read More
